Immunomodulation with eicosapentaenoic acid supports the treatment of autoimmune small-vessel vasculitis

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Hirahashi, Junichi ^a,h   Kawahata, Kimito ^a   Arita, Makoto ^b,i   Iwamoto, Ryo ^b   Hishikawa, Keiichi ^a   Honda, Mie ^b,i   Hamasaki, Yoshifumi ^a   Tanaka, Mototsugu ^a   Okubo, Koshu ^a   Kurosawa, Miho ^a   Takase, Osamu ^a   Nakakuki, Masanori ^c   Saiga, Kan ^d   Suzuki, Kazuo ^e   Kawachi, Shoji ^f   Tojo, Akihiro ^a   Seki, George ^a   Marumo, Takeshi ^g   Hayashi, Matsuhiko ^h   Fujita, Toshiro ^a,g  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c MOCHIDA PHARMACEUTICAL CO   (Japan)

^d NIPPON KAYAKU CO LTD   (Japan)

^e CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

^h KEIO UNIVERSITY   (Japan)

ⁱ Institute of Physical and Chemical Research   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ICOSAPENTAENOIC ACID; MESSENGER RNA;

AGED; ANIMAL; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; ENZYME IMMUNOASSAY; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; INBRED MOUSE STRAIN; MALE; MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AGED; ANIMALS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOMODULATION; MALE; MICE; MICE, INBRED STRAINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84923277934     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep06406     Document Type: Article

References (56)

1. Bosch, X., Guilabert, A., Espinosa, G. & Mirapeix, E. Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA 298, 655-669 (2007).
2. Harper, L. & Savage, C. O. ANCA-associated renal vasculitis at the end of the twentieth century: a disease of older patients. Rheumatology (Oxford) 44, 495-501 (2005).
3. Harper, L. Recent advances to achieve remission induction in antineutrophil cytoplasmic antibody-associated vasculitis. Curr. Opin. Rheumatol. 22, 37-42 (2010).
4. Hellmich, B. Update on the management of systemic vasculitis: what did we learn in 2009? Clin. Exp. Rheumatol. 28, 98 (2010).
5. Jones, R. B. et al. European Vasculitis Study Group. Rituximab versus Cyclophosphamide in ANCA-associated Renal Vasculitis. N. Engl. J. Med. 363, 211-220 (2010).
6. Stone, J. H. et al. Rituximab versus Cyclophosphamide for ANCA-associated Vasculitis. N. Engl. J. Med. 363, 221-232 (2010).
7. Little, M. A. et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann. Rheum. Dis. 69, 1036-1043 (2010).
8. Faurschou, M. et al. Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis. Arthritis Rheum. 60, 1187-1192 (2009).
9. Morgan, M. D. et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. Arthritis Rheum. 60, 3493-3500 (2009).
10. Woywodt, A. et al. Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet 361, 206-210 (2003).
11. Chironi, G. et al. Increased prevalence of subclinical atherosclerosis in patients with small-vessel vasculitis. Heart 93, 96-99 (2007).
12. de Leeuw, K. et al. Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann. Rheum. Dis. 64, 753-759 (2005).
13. Pagnoux, C., Chironi, G., Simon, A. & Guillevin, L. Atherosclerosis in ANCA-associated vasculitides. Ann. N. Y. Acad. Sci. 1107, 11-21 (2007).
14. Sherer, Y. & Shoenfeld, Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat. Clin. Pract. Rheumatol. 2, 99-106 (2006).
15. Shoenfeld, Y. et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112, 3337-3347 (2005).
16. Filer, A. D. et al. Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. Ann. Rheum. Dis. 62, 162-167 (2003).
17. Yokoyama, M. et al. Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentanoeic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369, 1090-1098 (2007).
18. Hirahashi, J., Jo, A., Ueda, K., Tojo, A. & Fujita, T. Successful treatment of antineutrophil cytoplasmic antibody-associated vasculitis with eicosapentaenoic acid. Ann. Intern. Med. 156, 755-756 (2012).
19. Kinjoh, K., Kyogoku, M. & Good, R. A. Genetic selection for crescent formation yields mouse strain with rapidly progressive glomerulonephritis and small vessel vasculitis. Proc. Natl. Acad. Sci. U. S. A. 90, 3413-3417 (1993).
20. Huugen, D et al. Antineutrophil cytoplasmic autoantibodies and pathophysiology: new insights from animal models. Curr Opin Rheumatol. 16, 4-8 (2004).
21. Neumann, I. et al. SCG/Kinjoh mice: A model of ANCA-associated crescentic glomerulonephritis with immune deposits. Kidney Int. 64, 140-148 (2003).
22. Serhan, C. N. et al. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal anti-inflammatory drugs and transcellular processing. J. Exp. Med. 192, 1197-1204 (2000).
23. Serhan, C. N. Resolution phases of inflammation: novel endogenous anti-inflammatory and pro-resolving lipids mediators and pathways. Annu Rev Immunol 25, 101-137 (2007).
24. Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K. & Serhan, C. N. Lipid mediator class switching during acute inflammation: signals in resolution. Nature Immunol. 2, 612-619 (2001).
25. Dona, M. et al. Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood 112, 848-855 (2008).
26. Yacoubian, S. & Serhan, C. N. New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases. Nat. Clin. Pract. Rheumatol. 3, 570-579 (2007).
27. Tjonahen, E. et al. Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem. Biol. 13, 1193-1202 (2006).
28. Morin, C. et al. Relaxing effects of 17(18)-EpETE on arterial and airway smooth muscles in human lung. Am J Physiol Lung Cell Mol Physiol. 296, L130-139 (2009).
29. Saiga, K. et al. NK026680, a novel suppressant of dendritic cell function, prevents the development of rapidly progressive glomerulonephritis and perinuclear antineutrophil cytoplasmic antibody in SCG/Kj mice. Arthritis Rheum 54, 3707-3715 (2006).
30. Tomizawa, K. et al. Reduction of MPO-ANCA epitopes in SCG/Kj mice by 15-deoxyspergualin treatment restricted by IgG2b associated with crescentic glomerulonephritis. Rheumatology 49, 1245-1256 (2010).
31. Halbwachs, L. & Lesavre, P. Endothelium-neutrophil interactions in ANCA-associated diseases. J. Am. Soc. Nephrol. 23, 1449-1461 (2012).
32. Nolan, S. L. et al. Mechanisms of ANCA-mediated leukocyte-endothelial cell interactions in vivo. J. Am. Soc. Nephrol. 19, 973-984 (2008).
33. Lau, D. et al. My eloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc. Natl. Acad. Sci. U. S. A. 102, 431-436 (2005).
34. Jerke, U. et al. Complement receptor Mac-1 is an adaptor for NB1 (CD177)-mediated PR3-ANCA neutrophil activation. J. Biol. Chem. 286, 7070-7081 (2011).
35. Hirahashi, J. et al. Mac-1 signaling via Src-family and Syk kinases results in elastase-dependent thrombohemorrhagic vasculopathy. Immunity. 25, 271-283 (2006).
36. Hirahashi, J. et al. Mac-1 (CD11b/CD18) links inflammation and thrombosis after glomerular injury. Circulation 120, 1255-1265 (2009).
37. Samantha, P. et al. Omega-3 Fatty Acids and Inflammation: Novel Interactions Reveal a New Step in Neutrophil Recruitment. In Vivo and In Vitro Inhibition of Monocyte Adhesion to Endothelial Cells and Endothelial Adhesion Molecules by Eicosapentaenoic Acid. PLoS. Biol. 7, e1000177 (2009).
38. Yamada, H. et al. In Vivo and In Vitro Inhibition of Monocyte Adhesion to Endothelial Cells and Endothelial Adhesion Molecules by Eicosapentaenoic Acid. Arterioscler. Thromb. Vasc. Biol. 28, 2173-2179 (2008).
39. Bettelli, E., Korn, T., Oukka, M. & Kuchroo, V. K. Induction and effector functions of T(H)17 cells. Nature 453, 1051-1057 (2008).
40. Nogueira, E. et al. Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol. Dial. Transplant. 25, 2209-2217 (2010).
41. Gan, P. Y. et al. Th17 cells promote autoimmune anti-myeloperoxidase glomerulonephritis. J. Am. Soc. Nephrol. 21, 925-931 (2010).
42. Valencia, X. & Lipsky, P. E. CD4 1 CD25 1 FoxP31 regulatory T cells in autoimmune diseases. Nat. Clin. Pract. Rheumatol. 13, 1193-1202 (2007).
43. Abdulahad, W. H. et al. Functional defect of circulating regulatory CD41 T cells in patients with Wegener's granulomatosis in remission. Arthritis Rheum. 56, 2080-2091 (2007).
44. Chavele, K. M. Regulation of myeloperoxidase-specific T cell responses during disease remission in antineutrophil cytoplasmic antibody-associated vasculitis: the role of Treg cells and tryptophan degradation. Arthritis Rheum. 62, 1539-1548 (2010).
45. Kelley, V. E., Ferretti, A., Izui, S. & Strom, T. B. A fish oil diet rich in eicosapentaenoic acid reduces cyclooxygenase metabolites and suppresses lupus in MRL-lpr mice. J. Immunol. 134, 1914-1919 (1985).
46. Halade, G. V. et al. Docosahexaenoic Acid-Enriched Fish Oil Attenuates Kidney Disease and Prolongs Median and Maximal Life Span of Autoimmune Lupus- Prone Mice. J. Immunol. 184, 5280-5286 (2010).
47. Halade, G. V. et al. Docosahexaenoic acid-enriched fish oil attenuates kidney disease and prolongs median and maximal life span of autoimmune lupus-prone mice. J. Immunol. 184, 5280-5286 (2010).
48. Iwami, D. et al. Purified Eicosapentaenoic Acid Induces Prolonged Survival of Cardiac Allografts and Generates Regulatory T Cells. Am J Transplant 9, 1294-1307 (2009).
49. Nakabayashi, K. et al. Tubulointerstitial nephritis without glomerular lesions in three patients with myeloperoxidase-ANCA-associated vasculitis. Clin. Exp. Nephrol. 13, 605-613 (2009).
50. Arita, M. et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 201, 713-722 (2005).
51. Prescott, S. M. & Stenson, W. F. Fish oil fix. Nat. Med. 11, 596-598 (2005).
52. Flower, R. J. & Perretti, M. Controlling inflammation: a fat chance? J. Exp. Med. 201, 671-674 (2005).
53. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. 1999. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 354, 447-455 (1999).
54. Floege, J. et al. Increased synthesis of extracellular matrix in mesangial proliferative nephritis. Kidney Int 40, 477-478 (1991).
55. Ishida-Okawara, A. et al. Neutrophil contribution to the crescentic glomerulonephritis in SCG/Kj mice. Nephrol. Dial. Transpl. 19,1708-1715 (2004).
56. Arita, M. Mediator lipidomics in acute inflammation and resolution. J. Biochem. 152, 313-319 (2012).